First-In-Class Antibodies

 

 

DKN-01 is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein 

DKN-01 is in clinical trials for gastroesophageal, hepatobiliary, gynecologic, and prostate cancer.

Lighter shade of green indicates a planned and not yet enrolling study.

​​

  • On November 7, 2019, Leap presented clinical data from its ongoing study of DKN-01 as a monotherapy or in combination with paclitaxel in patients with wnt activated gynecologic cancer at the SITC 2019 Meeting. Click here to view the poster.

  • On September 20, 2019, Leap presented clinical data from its ongoing study of DKN-01 as a monotherapy or in combination with paclitaxel in patients with wnt activated gynecologic cancer at the IGCS 2019 meeting. Click here to view the poster.

  • On April 1, 2019, Leap presented nonclinical data on the anti-tumor immune-modulatory activity of DKN-01 at the AACR 2019 meeting. Click here to view our poster.
     

  • On March 18, 2019, Leap presented clinical data from its ongoing study of DKN-01 as a monotherapy or in combination with paclitaxel in patients with wnt activated gynecologic cancer at the SGO 2019 meeting. Click here to view our poster.
     

  • On November 9, 2018, Leap presented nonclinical and clinical data specifically from its study of DKN-01 in combination with paclitaxel in gastroesophageal cancer at the SITC 2018 meeting. Click here to view our poster.
     

  • On October 21, 2018, Leap presented nonclinical and clinical data from its ongoing study of DKN-01 in combination with KEYTRUDA (pembrolizumab) in patients with esophagogastric cancer at the ESMO 2018 meeting. Click here to view our poster.
     

  • On April 16, 2018, Leap presented nonclinical and clinical data from its ongoing study of DKN-01 in combination with KEYTRUDA (pembrolizumab) in patients with esophagogastric cancer at the AACR 2018 Annual Meeting. Click here to view our poster.
     

  • On June 3, 2017, Leap presented data from its ongoing biliary tract cancer trial at the ASCO Annual Meeting. Click here to view our poster.
     

  • On April 2, 2017, Leap presented nonclinical and clinical data at the AACR Annual Meeting. Click here to 
    view our poster.

     

  • On January 19, 2017, Leap presented biomarker and efficacy data from its ongoing esophageal cancer trial at the ASCO GI meeting. Click here to view our poster.

  • On June 3, 2017, Dr. David Wise presented data at the 2017 ASCO annual meeting implicating DKK1 in hard-to-treat subtypes of prostate cancer. Click here to view the poster.

.

TRX518 is a novel, humanized anti-GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody designed to enhance the immune system’s anti-tumor response as an immune checkpoint agonist 

  • On April 1, 2019, MSKCC presented nonclinical data on TRX518 at the AACR 2019 meeting. Click here to view our poster.
     

  • On December 14, 2018, Leap presented data from its TRX518 combination studies with gemcitabine, pembrolizumab or nivolumab in advanced solid tumors at the ESMO IO meeting. Click here to view our poster.

  • On November 9, 2018, MSKCC presented data from its study of TRX518 monotherapy in advanced solid tumors at the SITC 2018 meeting. Click here to view our poster.
     

  • On June 5th, 2016, Leap presented early data from its single dose, dose escalation study in solid tumors at the ASCO Annual Meeting. Click here to view our poster.

 
Twiter Icon.png

© 2019 Leap Therapeutics, Inc.       All Rights Reserved